KCNK17 and cardiomyopathy: After classification into therapy-based risk groups, the association between KCNK17-rs2815063-A and LVEF reduction was stronger in the high and moderate cardiomyopathy risk groups (p = 9.6 × 10−4 and p = 1.4 × 10−4, respectively), compared to the low-risk group (p = 0.002).